Williamson Nicola, Morel Thomas, Bradley Helena, Lydon Aoife, Clifford Molly, Cronin Patrick, Biagioni Milton
UCB Pharma, Slough, UK.
UCB Pharma, Brussels, Belgium.
Neurol Ther. 2025 May 13. doi: 10.1007/s40120-025-00747-5.
Parkinson's disease (PD) is a progressive neurodegenerative condition, characterized by motor symptoms (MS) and non-motor symptoms (NMS). Currently, there is no global definition of advanced PD, but those in advanced stages experience diverse and severe symptomatology, and significant impacts to their health-related quality of life (HRQoL). This qualitative interview study aimed to explore the experience of symptoms and HRQoL impacts of advanced PD from the patient and clinician perspective and identify key concepts for assessment in PD clinical trials.
A targeted review of literature and qualitative concept elicitation interviews conducted with people with advanced PD (N = 20) and expert clinicians (N = 3) in the US aimed to identify symptoms of advanced PD and their impact on HRQoL. People with advanced PD (PwP) were defined as those diagnosed ≥ 5 years, experiencing ON/OFF motor fluctuations despite levodopa therapy, and classified as modified Hoehn and Yahr stages 2-4.
In total, 65 symptoms (48 NMS, 17 MS) were identified across the reviewed literature and qualitative interviews. The most frequently reported MS included tremor, rigidity, balance issues, and slowness of movement. Several NMS were also frequently reported by participants, including fatigue, cognitive dysfunction (e.g., difficulty thinking), neuropsychiatric symptoms (e.g., apathy), pain, sleep problems, urinary dysfunction, autonomic dysfunction, excessive daytime sleepiness, gastrointestinal dysfunction, and sensory dysfunction. Participants reported these to impact HRQoL, including daily activities, emotional functioning, physical functioning, social functioning, work/study, and financial well-being.
The study provides in-depth insights into the symptoms and HRQoL impacts experienced by those with advanced PD. A comprehensive conceptual model of the patient experience of advanced PD was developed to support the identification of relevant concepts for assessment in PD clinical trials.
帕金森病(PD)是一种进行性神经退行性疾病,其特征为运动症状(MS)和非运动症状(NMS)。目前,对于晚期帕金森病尚无全球统一的定义,但处于晚期的患者会经历多样且严重的症状,对其健康相关生活质量(HRQoL)产生重大影响。这项定性访谈研究旨在从患者和临床医生的角度探讨晚期帕金森病的症状体验及其对健康相关生活质量的影响,并确定帕金森病临床试验评估中的关键概念。
在美国,对晚期帕金森病患者(N = 20)和专家临床医生(N = 3)进行了针对性的文献综述和定性概念引发访谈,旨在确定晚期帕金森病的症状及其对健康相关生活质量的影响。晚期帕金森病患者(PwP)被定义为那些诊断时间≥5年、尽管接受左旋多巴治疗仍有开/关运动波动且被分类为改良Hoehn和Yahr分期2 - 4期的患者。
在综述文献和定性访谈中总共确定了65种症状(48种非运动症状,17种运动症状)。最常报告的运动症状包括震颤、僵硬、平衡问题和运动迟缓。参与者还经常报告几种非运动症状,包括疲劳、认知功能障碍(如思维困难)、神经精神症状(如冷漠)、疼痛、睡眠问题、排尿功能障碍、自主神经功能障碍、日间过度嗜睡、胃肠功能障碍和感觉功能障碍。参与者报告这些症状会影响健康相关生活质量,包括日常活动、情绪功能、身体功能、社交功能以及工作/学习和经济状况。
该研究深入洞察了晚期帕金森病患者所经历的症状及其对健康相关生活质量的影响。构建了晚期帕金森病患者体验的综合概念模型,以支持确定帕金森病临床试验评估中的相关概念。